Trevi Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Trevi Therapeutics, Inc. (TRVI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.58 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 405.25K shares, a 53.80% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.18M shares, a 27.22% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 2.25K shares, a 71.88% decline year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 237.40K shares, a 56.84% decline year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.00M shares, a 11.89% decline from fiscal 2024.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.40M shares, a 117.76% increase from fiscal 2023.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.56M shares, a 6.34% decline from fiscal 2022.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.67M shares, a 13.10% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 405.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 3.58M shares 10-Q · filed 2026-08-06 | 3.58M shares derived: sum of 3 quarters · filed 2026-08-06 | 3.82M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 3.18M shares 10-Q · filed 2026-05-05 | 3.18M shares derived: sum of 2 quarters · filed 2026-05-05 | 3.42M shares derived: sum of 3 quarters · filed 2026-05-05 | 3.68M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 2.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 239.65K shares derived: sum of 2 quarters · filed 2026-03-17 | 503.15K shares derived: sum of 3 quarters · filed 2026-03-17 | 3.00M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 237.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 500.90K shares derived: sum of 2 quarters · filed 2025-11-13 | 3.00M shares 10-Q · filed 2025-11-13 | 3.01M shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 263.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.76M shares 10-Q · filed 2025-08-07 | 2.77M shares derived: sum of 3 quarters · filed 2025-08-07 | 3.32M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 2.50M shares 10-Q · filed 2025-05-08 | 2.50M shares derived: sum of 2 quarters · filed 2025-05-08 | 3.05M shares derived: sum of 3 quarters · filed 2025-05-08 | 3.36M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 8.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 558.00K shares derived: sum of 2 quarters · filed 2025-03-18 | 863.00K shares derived: sum of 3 quarters · filed 2025-03-18 | 3.40M shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 550.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 855.00K shares derived: sum of 2 quarters · filed 2024-11-06 | 3.40M shares 10-Q · filed 2024-11-06 | 3.40M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 305.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.85M shares 10-Q · filed 2024-08-08 | 2.85M shares derived: sum of 3 quarters · filed 2024-08-08 | 2.85M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 2.54M shares 10-Q · filed 2024-05-07 | 2.54M shares derived: sum of 2 quarters · filed 2024-05-07 | 2.54M shares derived: sum of 3 quarters · filed 2024-05-07 | 2.79M shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 1.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | 1.50K shares derived: sum of 2 quarters · filed 2024-03-20 | 243.50K shares derived: sum of 3 quarters · filed 2024-03-20 | 1.56M shares 10-K · filed 2024-03-20 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 242.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.56M shares 10-Q · filed 2023-11-09 | 1.88M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 242.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.56M shares 10-Q · filed 2023-08-10 | 1.88M shares derived: sum of 3 quarters · filed 2023-08-10 | 1.97M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 1.32M shares 10-Q · filed 2023-05-11 | 1.64M shares derived: sum of 2 quarters · filed 2023-05-11 | 1.73M shares derived: sum of 3 quarters · filed 2023-05-11 | 1.85M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 317.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 410.50K shares derived: sum of 2 quarters · filed 2023-03-16 | 531.50K shares derived: sum of 3 quarters · filed 2023-03-16 | 1.67M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 93.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 214.50K shares derived: sum of 2 quarters · filed 2022-11-10 | 1.35M shares 10-Q · filed 2022-11-10 | 1.35M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 121.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.26M shares 10-Q · filed 2022-08-11 | 1.26M shares derived: sum of 3 quarters · filed 2022-08-11 | 1.37M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 1.14M shares 10-Q · filed 2022-05-12 | 1.14M shares derived: sum of 2 quarters · filed 2022-05-12 | 1.25M shares derived: sum of 3 quarters · filed 2022-05-12 | 1.54M shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 112.00K shares derived: sum of 2 quarters · filed 2022-03-17 | 401.00K shares derived: sum of 3 quarters · filed 2022-03-17 | 1.48M shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 111.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 400.00K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.47M shares 10-Q · filed 2021-11-10 | 1.54M shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 289.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 1.36M shares 10-Q · filed 2021-08-12 | 1.43M shares derived: sum of 3 quarters · filed 2021-08-12 | 1.52M shares derived: sum of 4 quarters · filed 2021-08-12 |
| 2021-03-31 | 1.07M shares 10-Q · filed 2021-05-13 | 1.14M shares derived: sum of 2 quarters · filed 2021-05-13 | 1.23M shares derived: sum of 3 quarters · filed 2021-05-13 | 1.31M shares derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | 70.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 153.75K shares derived: sum of 2 quarters · filed 2021-03-25 | 234.27K shares derived: sum of 3 quarters · filed 2021-03-25 | 764.58K shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 83.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 164.27K shares derived: sum of 2 quarters · filed 2020-11-12 | 694.58K shares 10-Q · filed 2020-11-12 | 698.58K shares derived: sum of 4 quarters · filed 2020-11-12 |
| 2020-06-30 | 80.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | 610.83K shares 10-Q · filed 2020-08-13 | 614.83K shares derived: sum of 3 quarters · filed 2020-08-13 | 622.33K shares derived: sum of 4 quarters · filed 2020-11-12 |
| 2020-03-31 | 530.31K shares 10-Q · filed 2020-05-07 | 534.31K shares derived: sum of 2 quarters · filed 2020-05-07 | 541.81K shares derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-12-31 | 4.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 11.50K shares derived: sum of 2 quarters · filed 2020-11-12 | 678.60K shares 10-K · filed 2020-03-16 | |
| 2019-09-30 | 7.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 674.60K shares 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | 667.10K shares 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |